Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pharmacovigilance

EMA launches initiative to improve collection of drug information through patient registries

The European Medicines Agency (EMA), headquarters pictured, wants to specifically identify the challenges drug manufacturers and regulators face in using existing registries because of the ways the data is currently collected

Source: Shutterstock.com

The European Medicines Agency (pictured) wants to identify the challenges drug manufacturers and regulators face in using existing patient registries

The European medicines safety watchdog is reviewing existing national and international patient registries in an attempt to improve and standardise data collection.

The European Medicines Agency (EMA) wants specifically to identify the challenges drug manufacturers and regulators face in using existing registries to monitor the safety and efficacy of authorised medicines because of the different ways data are currently collected and presented.

It will look at the existing network of registries held by manufacturers, physician organisations, national agencies and others, and consider establishing new registries if it discovers a gap in provision.

A cross-committee EMA task force has been established to lead the initiative. The task force will produce a strategy that will be tested to see whether it meets the needs and expectations of regulators, drug companies and others. The pilot is expected to run for two years.

“The aim of the pilot phase is not to make decisions about the need for a registry or to accelerate the granting of a market authorisation but to test whether such a planned, collaborative approach is successful in facilitating robust data collection,” says the EMA.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069524

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The European Medicines Agency (EMA), headquarters pictured, wants to specifically identify the challenges drug manufacturers and regulators face in using existing registries because of the ways the data is currently collected

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.